• Researcher Profile

    Mark W. Kieran, MD, PhD

     
    Mark W. Kieran, MD, PhD

    Top Doctor

     
    Director, Pediatric Medical Neuro-Oncology
    Institute Physician


    Associate Professor of Pediatrics, Harvard Medical School

    Center/Program

    Pediatric Brain Tumors

    Office phone: 617-632-4386
    Fax: 617-632-4897
    Email: mark_kieran@dfci.harvard.edu

    Preferred contact method: email

    View Physician Profile
     
     

    Research Department

    Pediatric Oncology

    Interests

    Neuro-oncology, Experimental therapies, Anti-angiogenesis, Phase 1/Phase 2 trials

    Area of Research

    Novel Agents for Pediatric Brain Tumors

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Shields Warren 331
    Boston, MA 02215

    Biography

    Dr. Kieran received his PhD in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. He completed postgraduate training in molecular biology at the Pasteur Institute in Paris. After a pediatric residency in Montreal at McGill University, he received postdoctoral education at Boston Children’s Hospital (BCH). In 1998, he became director of Pediatric Medical Neuro-Oncology at Dana-Farber/Boston Children’s. In addition to his role in the treatment of patients with brain tumors and the development of novel agents for the treatment of recurrent tumors, he continues to focus his laboratory efforts on angiogenesis agents from work he started in the laboratory of the late Dr. Judah Folkman.

    Recent Awards

    • America's Top Doctors for Cancer, Castle Connolly, 2014
    • America's Top Physicians, Showmark, 2014
    • Marquis Who's Who in Medicine and Healthcare, 2014
    • Science and Medicine Award, Progeria Research Foundation, 2014
    • Top Doctors in Boston, Boston Magazine, 2014
    • America's Top Doctors for Cancer, Castle Connolly, 2013
    • Marquis Who's Who in Medicine and Healthcare, 2013
    • Top Doctors in Boston, Boston Magazine, 2013
    • America's Top Doctors for Cancer, Castle Connolly, 2012
    • Marquis Who's Who in Medicine and Helathcare, 2012
    • Top Doctors in Boston, Boston Magazine, 2012
    • America's Top Doctors for Cancer, Castle Connolly, 2011
    • Marquis Who's Who in Medicine and Healthcare, 2011
    • Stephen Sallan Leadership Award in Pediatric Oncology, Dana-Farber Cancer Institute, 2011
    • Top Doctors in Boston, Boston Magazine, 2011
    • America's Top Doctors for Cancer, Castle Connolly, 2010
    • Appreciation in Teaching Award, University of Constantine, Algeria, 2010
    • Billy Grey Research Chairman Award, National Brain Tumor Society Meeting, San Francisco, 2010
    • Mill Foundation for Kid's Above and Beyond Award, Foundations Award, Southington, CT, 2010
    • Top Doctors in Boston, Boston Magazine, 2010
    • America's Top Doctors for Cancer, Castle Connolly, 2009
    • Excellence Award, Society of Neurosurgeons, Egypt, 2009
    • Top Doctors in Boston, Boston Magazine, 2009

    Research

    Novel Agents for Pediatric Brain Tumors

    The prognosis of patients with primary brain tumors remains poor despite major advances in neurosurgery and radiation oncology. Recently, several novel chemotherapeutic and biologic agents have become available that offer new approaches to therapy. Our laboratory selects promising agents and evaluates them in human tumors that have been orthotopically implanted into mice. This process quickly moves potential therapies into the clinic. At present, more than five such projects are ongoing in conjunction with different groups at DFCI, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, and Children's Hospital.

    Biologic correlates of brain tumors
    In conjunction with a number of groups, we have examined a series of tumor specimens from adult and pediatric patients to evaluate the expression of abnormal signaling pathways. The increasing availability of small-molecule inhibitors of many cell-surface signaling receptors may open the door to a series of clinical trials. To date, this work has focused on the pathways of the epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR), and ErbB2 receptor. The first national clinical trial based on this work is already under way.

    Antiangiogenesis
    In collaboration with the laboratory of Dr. Judah Folkman, we have initiated experiments that examine the antiangiogenic effects of a number of available agents, such as endostatin, as well as others whose activity involves novel pathways. As we move forward into clinical trials with these agents, being used alone or in combination with standard chemotherapy or radiation, we can better define their spectrum of activity and toxicity. This work also focuses on developing a series of surrogate markers of activity for these agents, so that their use in humans can be optimized for antitumor activity.

View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now